0.730
-0.20 (-21.76%)
| Previous Close | 0.933 |
| Open | 0.780 |
| Volume | 1,118,599 |
| Avg. Volume (3M) | 602,701 |
| Market Cap | 16,334,793 |
| Price / Earnings (Forward) | 0.520 |
| Price / Sales | 3.16 |
| Price / Book | 0.240 |
| 52 Weeks Range | |
| Earnings Date | 13 May 2026 |
| Diluted EPS (TTM) | -5.76 |
| Total Debt/Equity (MRQ) | 1.47% |
| Current Ratio (MRQ) | 0.370 |
| Operating Cash Flow (TTM) | -23.55 M |
| Levered Free Cash Flow (TTM) | 15.85 M |
| Return on Assets (TTM) | -25.32% |
| Return on Equity (TTM) | -60.53% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Citius Pharmaceuticals, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.41% |
| % Held by Institutions | 5.69% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Heights Capital Management, Inc | 31 Dec 2025 | 799,934 |
| Asset Advisory Group, Inc. | 31 Mar 2026 | 59,011 |
| Arkadios Wealth Advisors | 31 Dec 2025 | 20,000 |
| 52 Weeks Range | ||
| Median | 6.00 (721.92%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 11 Mar 2026 | 6.00 (721.92%) | Buy | 0.910 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |